AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)

Stock Information for AzurRx BioPharma Inc.

Loading

Please wait while we load your information from QuoteMedia.